educational objectives metastatic breast cancer: scope of the problem
TRANSCRIPT
![Page 1: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/1.jpg)
![Page 2: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/2.jpg)
Educational Objectives
![Page 3: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/3.jpg)
Metastatic Breast Cancer: Scope of the Problem
![Page 4: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/4.jpg)
Metastatic Breast Cancer: General Treatment Considerations
![Page 5: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/5.jpg)
![Page 6: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/6.jpg)
Therapeutic Goals/Endpoints in MBC
![Page 7: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/7.jpg)
MBC: Impact of Chemotherapy
![Page 8: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/8.jpg)
Treatment Options for Advanced Breast Cancer
![Page 9: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/9.jpg)
![Page 10: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/10.jpg)
First-Line Chemotherapy Options
![Page 11: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/11.jpg)
Response Rates with Single-AgentChemotherapeutic Agents in MBC
![Page 12: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/12.jpg)
Highlights of the Evolution of Taxanes in Oncology
![Page 13: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/13.jpg)
Taxanes in the Treatment of MBC
![Page 14: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/14.jpg)
Conventional Taxanes: Pharmacologic and
Pharmacodynamic Differences
![Page 15: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/15.jpg)
Conventional Taxanes: Impact of Solvents
![Page 16: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/16.jpg)
Albumin Role: Natural Carrier ofHydrophobic Molecules in Humans
![Page 17: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/17.jpg)
Increased Intratumoral Concentration With nab-Paclitaxel
![Page 18: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/18.jpg)
Differentiating the Taxanes: Toxicity
![Page 19: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/19.jpg)
Making Taxanes Less “Tax-ing”
![Page 20: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/20.jpg)
Taxane Toxicities
![Page 21: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/21.jpg)
Randomized Comparison Between Taxanes
![Page 22: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/22.jpg)
Taxanes: Premedication Guidelines
![Page 23: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/23.jpg)
Taxane Hypersensitivity Reactions
![Page 24: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/24.jpg)
Anemia
![Page 25: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/25.jpg)
Differentiating the Taxanes: Efficacy
![Page 26: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/26.jpg)
Pivotal Phase III Trials of PaclitaxelSingle Agent and Combinations
![Page 27: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/27.jpg)
Pivotal Phase III Trials of DocetaxelSingle Agent and Combinations
![Page 28: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/28.jpg)
![Page 29: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/29.jpg)
TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast
Cancer
![Page 30: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/30.jpg)
![Page 31: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/31.jpg)
TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast
Cancer – OS
![Page 32: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/32.jpg)
TAX 311: Hematologic Toxicity
![Page 33: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/33.jpg)
TAX 311: Non-Hematologic Toxicity
![Page 34: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/34.jpg)
TAX 311: Quality of Life Analysis
![Page 35: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/35.jpg)
Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design
![Page 36: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/36.jpg)
Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results
![Page 37: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/37.jpg)
Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP
![Page 38: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/38.jpg)
Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS
![Page 39: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/39.jpg)
Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line
Patients)
![Page 40: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/40.jpg)
nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities
![Page 41: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/41.jpg)
nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities
![Page 42: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/42.jpg)
nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution
![Page 43: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/43.jpg)
Phase II Study of Weekly nab-Paclitaxel in Taxane-Refractory
MBC
![Page 44: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/44.jpg)
Taxanes: Cost-effectiveness Model
![Page 45: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/45.jpg)
Cost-effectiveness Model: Methodology (cont.)
![Page 46: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/46.jpg)
Costs per Cycle
![Page 47: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/47.jpg)
Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003)
![Page 48: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/48.jpg)
Treatment Costs per Toxicity for Taxane Therapy
![Page 49: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/49.jpg)
Cost-effectiveness Ratios
![Page 50: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/50.jpg)
Model Analysis of Total Costs
![Page 51: Educational Objectives Metastatic Breast Cancer: Scope of the Problem](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649f055503460f94c1a1af/html5/thumbnails/51.jpg)
Conclusions